stockrowBristol Myers Squibb Company (BMY) vs Pfizer Inc. (PFE)
- Bristol Myers Squibb Company BMY 62.55 −0.92%
- Pfizer Inc. PFE 29.20 −0.85%
Bristol Myers Squibb Company and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $170.3B against $129.0B — 1.3× the size. Bristol Myers Squibb Company trades at the lower P/E: 14.0× against 42.2×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 4.16% against 1.34%. Bristol Myers Squibb Company has the higher net margin (18.5% vs 6.34%) and the higher return on invested capital (13.2% vs 6.19%). Both pay a dividend; Pfizer Inc. yields more (7.18% vs 3.99%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Pfizer Inc. on 7.
Valuation
Profitability
| Metric | BMY | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 73.38% | 73.01% |
| Operating margin | 22.65% | 21.44% | 18.34% |
| Net margin | 18.47% | 6.34% | 7.31% |
| Free cash flow margin | 18.56% | 18.52% | 18.52% |
| Return on equity | 44.01% | 4.42% | 5.80% |
| Return on assets | 9.96% | 1.95% | 2.28% |
| Return on invested capital | 13.19% | 6.19% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack